DiaMedica Therapeutics Inc.: Form 10-K for the period ended Dec 31, 2020
Filed with the SEC on Mar 10, 2021 and accepted by EDGAR at Mar 10, 2021, 16:03 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2020-01-01 to 2020-12-31 | $8.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2020-01-01 to 2020-12-31 | −$12.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2020-01-01 to 2020-12-31 | $27.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2020-01-01 to 2020-12-31 | −$12.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2020-01-01 to 2020-12-31 | −$0.78 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2020-01-01 to 2020-12-31 | −$9.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2020-01-01 to 2020-12-31 | $47.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-12-31 | $7.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-12-31 | $27.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-12-31 | $28.1m | us-gaap:Assets |
| Current liabilities | At period end2020-12-31 | $2.0m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2020-12-31 | $26.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-21-005541. Last ingested by Listed: Oct 24, 2026, 15:09 ET. Listed shows no prices and gives no investment advice.